Literature DB >> 1607710

Survival for women and men with AIDS.

G F Lemp1, A M Hirozawa, J B Cohen, P A Derish, K C McKinney, S R Hernandez.   

Abstract

To compare trends in the length of survival for women and men after diagnosis of AIDS, data were analyzed for 139 women and 7045 men who were reported with AIDS in San Francisco between July 1981 and 31 December 1990. Patients were followed prospectively through 15 May 1991. The median survival for women (11.1 months) was significantly shorter than that for men (14.6 months). When data were stratified by year of diagnosis, significantly improved survival was observed in recent years for both women and men, although survival for women remained significantly shorter than that for men. Among those who received either zidovudine or 2',3'-dideoxyinosine, survival did not differ by gender. However, among those not receiving therapy, survival was significantly shorter for women. These results suggest that the shorter survival of women may be a result of factors other than gender, possibly including less use of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607710     DOI: 10.1093/infdis/166.1.74

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Ethnic and demographic variations in HIV/AIDS presentation at two London referral centres 1995-9.

Authors:  J Saul; J Erwin; J C Bruce; B Peters
Journal:  Sex Transm Infect       Date:  2000-06       Impact factor: 3.519

2.  Relationship of psychosocial factors to HIV disease progression.

Authors:  T L Patterson; W S Shaw; S J Semple; M Cherner; J A McCutchan; J H Atkinson; I Grant; E Nannis
Journal:  Ann Behav Med       Date:  1996-03

Review 3.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

4.  Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study.

Authors:  R Andersen; S Bozzette; M Shapiro; P St Clair; S Morton; S Crystal; D Goldman; N Wenger; A Gifford; A Leibowitz; S Asch; S Berry; T Nakazono; K Heslin; W Cunningham
Journal:  Health Serv Res       Date:  2000-06       Impact factor: 3.402

5.  Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS.

Authors:  Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2007-08

6.  Recovery of Pseudomonas aeruginosa in respiratory specimens from HIV positive patients being evaluated for Pneumocystis carinii pneumonia.

Authors:  R L Doyle; J J Doherty; L H Zimmerman
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

7.  Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Authors:  Diana C Lemly; Bryan E Shepherd; Todd Hulgan; Peter Rebeiro; Samuel Stinnette; Robert B Blackwell; Sally Bebawy; Asghar Kheshti; Timothy R Sterling; Stephen P Raffanti
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

8.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Authors:  A Cozzi Lepri; P Pezzotti; M Dorrucci; A N Phillips; G Rezza
Journal:  BMJ       Date:  1994-12-10

9.  Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients.

Authors:  Mitchell D Wong; William E Cunningham; Martin F Shapiro; Ronald M Andersen; Paul D Cleary; Naihua Duan; Hong Hu Liu; Ira B Wilson; Bruce E Landon; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

10.  Survival of men and women with AIDS: a comparative study.

Authors:  G M Iatrakis; P N Shah; J R Smith; V S Kitchen; S E Barton
Journal:  Genitourin Med       Date:  1994-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.